IMTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immatics NV (IMTX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish signals, the lack of recent positive news, weak financial performance, and absence of strong trading signals suggest that it is better to hold off on investing in this stock right now.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram (0.112), indicating upward momentum. However, RSI at 66.621 is neutral, and the stock is trading close to its pivot level (10.501). Resistance levels are at 11.005 and 11.316, while support levels are at 9.996 and 9.685.
Analysts from Jefferies and Mizuho have issued positive ratings and price targets ($18 and $25, respectively), citing potential upside from key clinical milestones.
The company's financials show a significant YoY revenue drop (-89.74%) and a net loss of -$50.54M, despite improvements in EPS and gross margin. Additionally, there are no recent news catalysts, no significant insider or hedge fund activity, and no recent congress trading data.
In Q3 2025, revenue dropped significantly (-89.74% YoY) to $5.19M. However, net income improved to -$50.54M (+489.79% YoY), and EPS increased to -0.42 (+425% YoY). Gross margin remained at 100%.
Analysts are optimistic, with Jefferies initiating a Buy rating and $18 price target, and Mizuho raising its price target to $25. Both firms highlight the company's potential upside from clinical developments.
